135 related articles for article (PubMed ID: 30768860)
21. Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study.
Zakkula A; Pulipati S; Dittakavi S; Bestha RM; Zainuddin M; Trivedi RK; Mullangi R
Drug Res (Stuttg); 2020 May; 70(5):233-238. PubMed ID: 32289835
[TBL] [Abstract][Full Text] [Related]
22. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
Courtney R; Wexler D; Radwanski E; Lim J; Laughlin M
Br J Clin Pharmacol; 2004 Feb; 57(2):218-22. PubMed ID: 14748822
[TBL] [Abstract][Full Text] [Related]
23. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Kraft WK; Chang PS; van Iersel ML; Waskin H; Krishna G; Kersemaekers WM
Antimicrob Agents Chemother; 2014 Jul; 58(7):4020-5. PubMed ID: 24798274
[TBL] [Abstract][Full Text] [Related]
24. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
25. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
26. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
[TBL] [Abstract][Full Text] [Related]
29. Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
Morcos PN; Moreira SA; Navarro MT; Bech N; Quatkemeyer A; Smith PF; Brennan BJ
J Pharm Pharmacol; 2014 Jan; 66(1):23-31. PubMed ID: 24117531
[TBL] [Abstract][Full Text] [Related]
30. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
31. Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
Menssen HD; Quinlan M; Kemp C; Tian X
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):385-394. PubMed ID: 30059193
[TBL] [Abstract][Full Text] [Related]
32. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
[TBL] [Abstract][Full Text] [Related]
34. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
35. Two-Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants.
Schueller O; Regev G; Singh N; Willson A; Beville M; Kanji N; Lohmer L; Patel J
Clin Pharmacol Drug Dev; 2024 May; 13(5):491-498. PubMed ID: 38345529
[TBL] [Abstract][Full Text] [Related]
36. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
37. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
[TBL] [Abstract][Full Text] [Related]
38. Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats.
Dixit A; Kiran V; Gabani BB; Mohd Z; Trivedi RK; Mullangi R
Biomed Chromatogr; 2020 Apr; 34(4):e4802. PubMed ID: 31998982
[TBL] [Abstract][Full Text] [Related]
39. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Verheijen RB; van der Biessen DAJ; Hotte SJ; Siu LL; Spreafico A; de Jonge MJA; Pronk LC; De Vos FYFL; Schnell D; Hirte HW; Steeghs N; Lolkema MP
Target Oncol; 2019 Feb; 14(1):67-74. PubMed ID: 30742245
[TBL] [Abstract][Full Text] [Related]
40. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
